CANF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Can Fite Biopharma Ltd (CANF) is not a strong buy for a beginner, long-term investor at this time. The stock lacks positive momentum, has no significant trading signals, and faces negative sentiment from analysts. Additionally, the financial performance shows no growth, and there are no recent catalysts or influential trades to support a bullish outlook.
The MACD is slightly positive but contracting, indicating weakening momentum. RSI is neutral at 56.446, and moving averages are converging, suggesting no clear trend. The stock closed below its pivot level (4.311), with support at 4.028 and resistance at 4.593, indicating limited upside potential in the short term.
NULL identified. No recent news, no positive trading signals, and no significant insider or hedge fund activity.
Analyst downgrade to Hold due to a reverse stock split, which often signals financial instability or an attempt to meet listing requirements. The stock also lacks momentum and has shown a regular market decline of -1.82%.
In Q4 2023, revenue remained flat at $155,000 YoY. Net income was -$1,652,000, EPS was -4.29, and gross margin was 100%, all showing no growth trends. The financials indicate a lack of profitability and no clear improvement.
Analyst Jason Kolbert downgraded the stock to Hold from Buy, citing the upcoming reverse stock split. No price target was provided, and the downgrade reflects negative sentiment.
